Effect of multiple subconjunctival conbercept injections as an adjuvant to the surgical treatment of pterygium: a prospective randomised comparative 6-month follow-up study

Abstract

Objective To evaluate the safety and efficacy of multiple subconjunctival injections of conbercept for pterygium patients after surgery. Methods As a prospective randomised interventional trial, 96 eyes from 96 patients with a tendency to recur were collected and divided randomly into conbercept and 5-fluorouracil groups on the 5th day after pterygium. All patients received three subconjunctival injections of conbercept (0.2 ml) or 5-fluorouracil (0.2 ml) on the 5th day (baseline), and 2 and 4 weeks postoperatively. The pterygium morphology, colour intensity, recurrence, and complications were recorded and analysed pre-1st injection and 1 day, 1 week, 1 month, 3 months, and 6 months post-3rd injection. Moreover, no patient was drop-out. Results There were striking differences between the two groups on post-3rd injections 1 day, 1 week, 1 month, 3 months, and 6 months (p = 0.001, 0.002, 0.000, 0.000, and 0.002, respectively) with respect to colour intensity: the eyes in conbercept group were lighter than the 5-Fu group. On post-3rd injection 6 months, prominent disparities existed between the two groups with respect to pterygium morphology (p = 0.006) and recurrence (p = 0.002), occurred in the conbercept group prior to the 5-Fu group. Moreover, corneal abrasions were not noted in the conbercept group, which was significantly less than the 5-Fu group (17/48; p = 0.000). There was no conspicuous discrepancy between the two groups with respect to subconjunctival haemorrhage (p = 0.789) and persistent epithelial defects (p = 0.078). Conclusion Multiple subconjunctival conbercept injections as an adjunct therapy for pterygium surgery was shown to be safe, effective, and well-tolerated.

Long-term clinical effects of intravitreal injections of conbercept for the treatment of choroidal neovascularization in patients with pathological myopia

“…These data indicate that Aflibercept was effective for the treatment of PM-CNV and could significantly improve the vision; however, it should be used on time to maximise the benefits of the drug. The safety of intravitreal anti-VEGF agents was also reported in many studies [30][31][32][33] . The RADIANCE, BRILLIANCE and LUMINOUS studies evaluated the use of ranibizumab for mCNV.…”

Efficacy and safety of anti-vascular endothelial growth factor agents in the treatment of primary pterygium

“…Characteristics of the enrolled studies were shown in Table 1 . A total of 19 RCTs were included ( 12 – 26 , 30 , 32 , 36 , 38 ). There were 18 English articles and 1 Chinese articles.…”

“…Although our previous meta-analysis ( 2 ) and a recently published paper by Zhang ( 31 ) revealed that bevacizumab reduced recurrence after pterygium surgery, the finding wasn't conclusively supported by researches thereafter and the data just focused on bevacizumab. Some other anti-VEGF agents, including ranibizumab ( 32 – 35 ), conbercept ( 36 ), and aflibercept ( 37 ) also showed different efficacy in management of pterygium. Overall, the current evidence does not convincingly support the use of anti-VEGF in pterygium surgery ( 10 ).…”

An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye

“…The study was conducted on 96 patients by giving them 3 subconjunctival injections of conbercept (with 0.2 mL) and 5 subconjunctival injections of 5-fluorouracil (with 0.2 mL). All the study data were collected from the fifth day after pterygium which is taken as a baseline to 2 to 4 weeks of postoperation . Sub tenon injections are yet another popular mode of administration.…”